DNA Damage Repair Inhibitors-Combination Therapies

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Genomic integrity is crucial for preventing cancer, maintained by complex DNA damage response and repair (DDR) pathways.
• Dysregulation of DDR pathways is linked to numerous malignancies, presenting opportunities for targeted cancer therapies.
• Poly(ADP-ribose) polymerase (PARP) inhibitors have shown success, prompting research into other DDR inhibitors.

Purpose of the Study:

• To review the current clinical research and therapeutic applications of inhibitors targeting key DNA damage response pathways.
• To focus on four major DDR pathways: ATR/CHK1, ATM/CHK2, DNA-PKcs, and polymerase θ.
• To discuss the potential of combining DDR inhibitors with conventional treatments like chemotherapy and radiation.

Main Methods:

• Literature review of clinical trials and research studies on DDR inhibitors.
• Analysis of the roles of ATR/CHK1, ATM/CHK2, DNA-PKcs, and polymerase θ pathways in cancer.
• Examination of combination therapy strategies involving DDR inhibitors.

Main Results:

• Inhibitors targeting ATR/CHK1, ATM/CHK2, DNA-PKcs, and polymerase θ are under active clinical investigation.
• These inhibitors show promise when used alone or in combination with chemotherapy, radiation, or other DDR-targeting agents.
• The clinical utility of these DDR inhibitors is being explored to address significant unmet needs in cancer treatment.

Conclusions:

• Targeting DDR pathways represents a promising strategy in oncology.
• Combination therapies involving DDR inhibitors may enhance treatment efficacy for various cancers.
• Further clinical research is essential to optimize the use of DDR inhibitors in cancer therapeutics.